Ruchit Patel is an antitrust partner in the firm’s London office and a member of the firm’s governing policy committee. He advises some of the largest companies in the world on matters before the European Commission, UK Competition and Markets Authority, UK sectoral regulators and UK High Court. He also has litigation experience before the UK Competition Appeal Tribunal.

Ruchit was included in Global Competition Review’s 2020 list of the top young antitrust lawyers in the world: the 40 under 40. Who’s Who Legal characterizes him as a “Future Leader” and comments that “Ruchit Patel is revered as an “skilled, flexible and sharp-minded competition law expert” who is “able to coordinate complex projects.”  Ruchit is also recognized in Chambers UK in the area of competition law, and GCR notes he is a “Future Leader.” Clients have commented in Who’s Who Legal that Ruchit is “a very experienced competition lawyer” who “focuses on strategy and results” and “is uniquely dedicated to ensuring his clients’ success” and is “able to coordinate complex projects.” Legal 500 also noted that Ruchit brings “an in-depth knowledge of Indian competition law.” 

Ruchit is a visiting lecturer at the Centre for Commercial Law Studies at Queen Mary University of London. He is a member of several committees, including the Competition Section of the English Law Society, the Law360 editorial board, and the editorial board of the IBA.


Representative Strategic Company Experience

  • Nippon Steel Corporation on its ~$14 billion bid for US Steel
  • Immunogen on the antitrust aspects of its sale to AbbVie valued ~$10.1 billion
  • AbbVie in its acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinson’s Disease
  • Bloomberg on antitrust aspects of its planned acquisition of Broadway Technology, a cutting-edge provider of high-performance front-office fintech solutions
  • Pfizer Inc. on several transactions, including Biohaven (~$12 billion), Global Blood Therapeutics (~$5.4 billion), Trillium Therapeutics Inc. ($2.26 billion), Medivation ($14 billion) and others
  • Medtronic on several transactions, including Covidien ($43 billion), Mazor Robotics ($1.64 billion), Affera (~$1 billion), Intersect ($1.1 billion) and others
  • Google on its acquisition of an interest in Reliance Jio Platforms valued at $4.5 billion
  • Acceleron Pharma on its approximately $11.5 billion sale to Merck
  • Sunovion Pharmaceuticals, a subsidiary of Japan’s Sumitomo Dainippon Pharma, in a billion-dollar worldwide co-development and co-commercialization agreement with Otsuka Pharmaceutical Co., Ltd. for four novel neurology drugs
  • Takeda Pharmaceutical Company Limited in an exclusive collaboration and license agreement with JCR Pharmaceuticals Co., Ltd. to commercialize JR-141 for the treatment of Hunter syndrome
  • Wright Medical Group N.V. on its agreement to be acquired by Stryker Corp. in a transaction with a total enterprise value of approximately $5.4 billion
  • Blue Coat on the European aspects of its sale to Symantec valued at over US$4 billion
  • Biomet, the divestiture buyer, on J&J’s US$21.3 billion acquisition of Synthes
  • Merck on its animal health joint venture with Sanofi-Aventis (ultimately abandoned). Awarded GCR “Deal of the Year” in 2011 in recognition of its size and complexity
  • Abbott on its US$4.5 billion acquisition of Solvay’s pharmaceuticals and diagnostics business, which was conditionally cleared at Phase I

Representative Private Equity Experience

  • Advent on its $4.25 billion acquisition of Baxter BioPharma Solutions
  • TPG on its $4 billion sale of McAfee Enterprise to STG
  • TPG on its $14 billion sale of McAfee Consumer to Advent International and Permira
  • TPG on its $4 billion sale of Wind River to Aptiv
  • Bain Capital on its US$18 billion acquisition of Toshiba Memory Corporation from Toshiba Corporation, by way of a Bain Capital-led consortium including Apple, Seagate Technology, Kingston Technology, Hoya, Dell Technologies and SK Hynix
  • Baring Private Equity Asia on its ~$7 billion merger with EQT
  • Bain Capital on its $8.5 billion acquisition of Hitachi Metals
  • Advent International on its $2.7 billion acquisition of Nielsen IQ
  • Warburg Pincus and General Atlantic on their $2 billion acquisition of Santander Asset Management


  • Google with several multi-jurisdictional competition law investigations
  • The Coca-Cola Company in several transactions and in defence of its commercialization practices
  • SK Hynix on settlement negotiations with the European Commission in DRAM
  • IBM with a complaint to the European Commission in relation to “midrange” servers
  • Metlac in defence of the Competition Commission’s decision to prohibit AkzoNobel’s acquisition of Metlac
  • Boots plc in relation to Celesio’s appeal of the OFT’s decision in Boots/ Alliance Unichem in the Competition Appeal Tribunal
  • An intervener in relation to Ofgem’s decision to fine British Gas for exclusionary policy in relation to gas and electricity matter

Areas of Practice


    Ropes & Gray International LLP is a limited liability partnership registered in Delaware, United States of America and is a recognised body regulated by the Solicitors Regulation Authority (with registered number 521000).